Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

An Artificial Intelligence-Powered Supportive Care Chatbot to Address the Supportive Care Needs of Young Adult Cancer Survivors

13. august 2026 opdateret af: University of Michigan Rogel Cancer Center

Feasibility, Usability, and Acceptability of an AI-Powered MASCC Supportive Care Platform Among Young Adults With Cancer

This clinical trial studies whether an artificial intelligence (AI)-powered supportive care chatbot is helpful for addressing the supportive care needs of young adult cancer survivors. Young adult cancer survivors often experience ongoing and distressing symptoms following treatment, including extreme tiredness and lack of energy, anxiety, and difficulty sleeping. Young adult cancer survivors report a variety of strategies to self-manage these symptoms; however, there remains a gap in targeted interventions focused on the needs in young adult survivors. The AI-powered supportive care chatbot is designed to provide evidence-based information on supportive care for young adult cancer survivors. Users interact with the chatbot by entering free-text questions or selecting from predefined topics to receive tailored educational responses related to supportive care across the cancer continuum, including treatment effects, symptom management, care transitions, and life after cancer. The AI-powered supportive care chatbot may be an effective way to help address the supportive care needs of young adult cancer survivors.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

30

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48109
        • University of Michigan Rogel Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Robert Knoerl

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • 18 - 39 years old
  • Able to speak/read English
  • Completed primary cancer treatment (e.g., surgery, radiation, chemotherapy, immunotherapy) at least one month prior to the time of consent. Although, participants will be eligible if they are receiving maintenance treatments
  • Report at least one moderate to severe symptom, side effect, or supportive care concern from cancer or its treatment
  • Able to access Wi-Fi/internet
  • Willing to complete surveys electronically

Exclusion Criteria:

  • Completed cancer treatment more than three years ago

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Supportive care (AI-powered supportive care chatbot)
Patients interact with AI-powered supportive care chatbot in a self-directed manner for 4 weeks. Following the initial 4-week use period, patients choose to either continue to use the chatbot for an additional 8 weeks or conclude study participation.
Hjælpestudier
Hjælpestudier
Interact with AI-powered supportive care chatbot
Andre navne:
  • AI Intervention
  • AI-based Intervention

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Acceptability of AI-powered supportive care chatbot
Tidsramme: At end of intervention, assessed up to 12 weeks
Acceptability will be supported if mean scores on the Acceptability E-Scale are ≥ 4 (on a 5-point scale). Will be described (i.e., means, medians, standard deviations, and ranges) at the post-intervention time point.
At end of intervention, assessed up to 12 weeks
Demand of AI-powered supportive care chatbot
Tidsramme: Up to 12 months
Demand will be demonstrated by successful recruitment of the target sample (N=30) within 12 months.
Up to 12 months
Implementation of AI-powered supportive care chatbot
Tidsramme: During intervention use, assessed up to 12 weeks
Implementation will be assessed by engagement with the chatbot, defined as ≥ 70% of participants reporting at least one use per week during the initial 4-week period, rather than a fixed duration of use, given the self-directed nature of the intervention. Will be described (i.e., means, medians, standard deviations, and ranges) weekly. Given the pilot nature of the study, no hypothesis testing or formal comparisons will be conducted.
During intervention use, assessed up to 12 weeks
Retention
Tidsramme: Up to 12 weeks
Retention will be considered feasible if ≥ 80% of participants complete 4-week assessments, and ≥ 50% elect to continue to the optional extended use period.
Up to 12 weeks
Usability of AI-powered supportive care chatbot
Tidsramme: At end of intervention, assessed up to 12 weeks
Usability will be supported if mean System Usability Scale scores are ≥ 70, indicating acceptable usability. Will be described (i.e., means, medians, standard deviations, and ranges) at the post-intervention time point.
At end of intervention, assessed up to 12 weeks
Patient Reported Outcomes Measurement Information System measure
Tidsramme: At baseline, 4 weeks, and/or 12 weeks
Will be summarized using descriptive statistics (e.g., means, medians, standard deviations, and ranges) at each time point. Changes over time (baseline, post-intervention, as applicable) will be examined descriptively.
At baseline, 4 weeks, and/or 12 weeks
Digital Health Literacy Scale
Tidsramme: At baseline
Will be summarized using descriptive statistics (e.g., means, medians, standard deviations, and ranges) at the baseline time point. The Digital Health Literacy Scale is a 0 to 12 point score (based on 3 items), with higher scores indicating greater digital health care literacy.
At baseline
Interview themes and subthemes
Tidsramme: At end of intervention, assessed up to 12 weeks
The audio-recorded interviews will be transcribed verbatim by a professional transcription company and verified for accuracy by another study team member. The finalized transcripts will be imported into NVivo 12 (QSR International Pty Ltd). Inductive content analysis will be used to analyze the interview transcripts. Two study team members will review the transcripts and the interview guide to create an initial list of codes. Three transcripts will be independently coded using the initial codebook. After three interviews are coded, two study team members will meet to resolve any coding discrepancies and to revise the codebook further. The same process will be repeated after three more interviews are coded. After the codebook is finalized, one study team member will code the remaining interviews. Subsequently, the study team will meet as a group to review the transcripts in their entirety, making sense of the data and generating potential major themes and subthemes.
At end of intervention, assessed up to 12 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Robert Knoerl, University of Michigan Rogel Cancer Center

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. oktober 2026

Primær færdiggørelse (Anslået)

1. oktober 2028

Studieafslutning (Anslået)

1. oktober 2028

Datoer for studieregistrering

Først indsendt

30. juli 2026

Først indsendt, der opfyldte QC-kriterier

13. august 2026

Først opslået (Faktiske)

19. august 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. august 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. august 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • UMCC 2026.025
  • NCI-2026-05454 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
  • HUM00288074 (Anden identifikator: University of Michigan Rogel Cancer Center)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified participant data will be shared with other researchers upon reasonable request and execution of a data transfer agreement.

IPD-delingstidsramme

After publication of results and within 7 years after study completion.

IPD-delingsadgangskriterier

De-identified participant data will be shared with other researchers upon reasonable request and execution of a data transfer agreement.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner